These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31933016)

  • 1. Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.
    Williams DW; Li Y; Dastgheyb R; Fitzgerald KC; Maki PM; Spence AB; Gustafson DR; Milam J; Sharma A; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Weber KM; Xu Y; Rubin LH
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):181-194. PubMed ID: 31933016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations between Antiretrovirals and Cognitive Function in Women with HIV.
    Rubin LH; Li Y; Fitzgerald KC; Dastgheyb R; Spence AB; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Haughey NJ; Ofotokun I; Fischl MA; Konkle-Parker D; Xu Y; Williams DW
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):195-206. PubMed ID: 32212091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.
    Rubin LH; O'Halloran JA; Williams DW; Li Y; Fitzgerald KC; Dastgheyb R; Damron AL; Maki PM; Spence AB; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Xu Y
    J Neuroimmune Pharmacol; 2023 Jun; 18(1-2):1-8. PubMed ID: 35178611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
    Checa A; Castillo A; Camacho M; Tapia W; Hernandez I; Teran E
    AIDS Res Ther; 2020 Jul; 17(1):47. PubMed ID: 32727488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV.
    Siddiqui M; Moore TJ; Long DM; Burkholder GA; Willig A; Wyatt C; Heath S; Muntner P; Overton ET
    AIDS Res Hum Retroviruses; 2022 Sep; 38(9):735-742. PubMed ID: 35778856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
    Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
    AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common antiretroviral combinations are associated with somatic depressive symptoms in women with HIV.
    Parra-Rodriguez L; O'Halloran J; Wang Y; Jin W; Dastgheyb RM; Spence AB; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Maki PM; Xu Y; Rubin LH
    AIDS; 2024 Feb; 38(2):167-176. PubMed ID: 37773048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in depressive symptoms after antiretroviral therapy initiation in people with HIV in Rakai, Uganda.
    Nakasujja N; Vecchio AC; Saylor D; Lofgren S; Nakigozi G; Boulware DR; Kisakye A; Batte J; Mayanja R; Anok A; Reynolds SJ; Quinn TC; Pardo CA; Kumar A; Gray RH; Wawer MJ; Sacktor N; Rubin LH
    J Neurovirol; 2021 Aug; 27(4):519-530. PubMed ID: 34333739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
    Mellgren Å; Eriksson LE; Reinius M; Marrone G; Svedhem V
    PLoS One; 2020; 15(12):e0242710. PubMed ID: 33362248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
    Koss CA; Natureeba P; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Clark TD; Achan J; Ruel T; Nzarubara B; Kamya MR; Havlir DV; Cohan D
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):128-35. PubMed ID: 25072616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
    Torriani FJ; Komarow L; Parker RA; Cotter BR; Currier JS; Dubé MP; Fichtenbaum CJ; Gerschenson M; Mitchell CK; Murphy RL; Squires K; Stein JH;
    J Am Coll Cardiol; 2008 Aug; 52(7):569-76. PubMed ID: 18687253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.